BTAI - BioXcel Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
53.15
-0.34 (-0.64%)
As of 12:26PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close53.49
Open54.41
Bid53.26 x 800
Ask53.41 x 1000
Day's Range52.56 - 54.84
52 Week Range3.76 - 61.50
Volume168,867
Avg. Volume467,101
Market Cap1.074B
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 3 Pharmaceutical Stocks With Major Catalysts Approaching
    TipRanks

    3 Pharmaceutical Stocks With Major Catalysts Approaching

    Even during economic downturns, one fact remains resolute: pharma stocks represent the ultimate risk/reward plays. Out on Wall Street, the sector has become known for its high volatility. How did it earn this reputation? It comes down to the nature of the industry itself.Unlike companies in other areas of the market, pharma stocks depend less on earnings results, and more on clinical data and regulatory decisions. As the latter determine the trajectory of these stocks, a single piece of good news can act as a catalyst that sends shares skyrocketing.That being said, shares can plummet just as easily should a company publish lackluster data or if approvals don’t come through. For this reason, in-depth due diligence is necessary before pulling the trigger on a name in this sector.Today, we’ll look at three pharma stocks recommended by Sumant Kulkarni, a top-rated analyst from Canaccord. Kulkarni believes these three tickers could be propelled higher by upcoming clinical trial results that could be huge catalysts for each one. Indeed, according to TipRanks’ database, each ticker scores a “Strong Buy” consensus rating from the rest of the Street and boasts substantial upside potential.Zynerba Pharmaceuticals (ZYNE)Focused on developing transdermally-delivered cannabinoid therapeutics, Zynerba Pharmaceuticals wants to improve the lives of patients suffering from neuropsychiatric conditions like Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). On the heels of its recent positive data readout and more potential catalysts ahead, Kulkarni believes ZYNE's $5.50 share price looks like a steal.On May 27, ZYNE released data from its Phase 2 open-label BRIGHT trial studying Zygel (ZYN002), a transdermal synthetic cannabidiol gel, in ASD. Even though it’s still early, the data indicated that the asset could serve as an add-on treatment to the standard of care for the behavioral symptoms associated with the condition.Expounding on this, Kulkarni noted, “Specifically, Zygel ‘hit’ on all five sub-scales of the Aberrant Behavior Checklist - Community (ABC-C), and also on the Parent-Rated Anxiety Scale - ASD (PRAS-ASD), while retaining the relatively-benign safety/tolerability profile seen so far.” While certainly promising, focus remains primarily on the data readout for the double-blind, placebo-controlled, CONNECT-FX pivotal trial evaluating Zygel in FXS, which is slated for later this month. “Our view is there is limited read-through from today's ASD data to FXS, but we are encouraged Zygel appears to have activity on scales associated with social parameters. Our stock thesis is unchanged in that FXS has no approved products and trial data remain difficult to call, but we believe ZYNE presents significant opportunity for risk-tolerant investors going into the FXS data set,” Kulkarni commented. If that wasn’t enough, Kulkarni points to several other possible catalysts on the horizon. The verdict from ZYNE’s discussions with the FDA regarding Zygel’s DEE pivotal program is set to come in the next few weeks, with top-line results from the Phase 2 open-label INSPIRE study for Zygel in 22q coming the following quarter.To this end, Kulkarni rates ZYNE a Buy along with an $18 price target. This target implies shares could more than double in the next year. (To watch Kulkarni’s track record, click here) Like Kulkarni, other analysts also take a bullish approach. ZYNE’s Strong Buy consensus rating breaks down into 6 Buys and zero Holds or Sells. Given the $19.17 average price target, the upside potential lands at 249%. (See Zynerba stock analysis on TipRanks)BioXcel Therapeutics (BTAI)Next up we have BioXcel Therapeutics, which uses artificial intelligence (AI) to develop cutting-edge medicines across neuroscience and immuno-oncology. With two major potential catalysts in the near-term, it’s no wonder Wall Street focus has locked in on this name.On June 11, the company revealed that the first patient had been enrolled in RELEASE, its Phase 1b/2 trial assessing the use of BXCL501, a sublingual dexmedetomidine film, in treating opioid withdrawal symptoms.Weighing in on the implications of this development, Kulkarni said, “This on-time start means BXCL501 will move into a sub-chronic dosing setting vs. acute/rescue therapy for agitation where it is farther along in development. This move also ties into BTAI's strategy to build a broader/leading franchise around agitation, which is an approach that we continue to view as smart. We also remain impressed by management's ability to hit stated timelines, and look forward to RELEASE top-line data in 1Q21.”Speaking to the opportunity in this indication, there’s already a significant unmet need, and COVID-19 could potentially make the situation worse for many patients. As a result, Kulkarni projects a 2023 launch and unadjusted peak sales of $472 million in 2030.However, before this, data on the candidate’s use in treating agitation caused by other conditions is expected. Kulkarni is looking forward to the data readout for the Phase 3 SERENITY trial of BXCL501 in agitation in schizophrenia and bipolar disorder this July as well as the results from the Phase 1b/2 TRANQUILITY trial in dementia-induced agitation in mid-2020.Calling the above readouts “two key catalysts”, Kulkarni noted, “We continue to believe SERENITY data will come before TRANQUILITY, and like the risk-reward for the stock going into these events based on solid Phase 1b/2 data in schizophrenia, and proof-of-concept data in dementia.” The analyst added, “We model a probability of approval estimate of 75% for agitation in schizophrenia/bipolar disorder and our 2030E peak unadjusted sales are $313 million. We model 65% probability of approval in agitation in dementia, and our 2030E unadjusted peak sales are $584 million.”All of the above combined with other possible catalysts involving BXCL501 and BTAI’s other candidate, BXCL701, slated for 2H20 prompted Kulkarni to keep a Buy recommendation and $71 price target on the stock. Should the target be met, a twelve-month gain of 34% could be in store.All in all, other analysts are on the same page. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $89 average price target, which is more aggressive than Kulkarni’s, the upside potential comes in at 68%. (See BioXcel stock analysis on TipRanks)Intra-Cellular Therapies (ITCI)Founded on Nobel-prize winning research that uncovered how therapies impact the inner-workings of cells in the body, Intra-Cellular Therapies hopes to address the unmet needs of patients battling complex psychiatric and neurologic diseases. Ahead of an important possible catalyst, Kulkarni thinks ITCI is “significantly undervalued”.It should be noted that its most recent quarter saw the company achieve a major milestone as its recently-approved Caplyta product, lumateperone, for schizophrenia, was launched. Only on the market since March 23, the asset generated just under $1 million in sales, with Kulkarni calling for $1.1 million. This is impressive as the estimate wasn’t updated after the onset of the COVID-19 pandemic.“Given the current environment, we get the sense that ITCI has been nimble enough to adapt well and has also made good progress with payers... We continue to believe Caplyta could generate meaningful sales in schizophrenia, and at these levels we are BUYERS on this opportunity alone.” Kulkarni explained.Also noteworthy for Kulkarni, though, is the publication of data from the Phase 3 global adjunct trial for lumateperone in bipolar depression, which is set to come in mid-20. Additionally, the analyst points out that ITCI should provide updates regarding its discussions with the FDA on this indication.“That said, we also like the stock going into the mid-20 Phase 3 data for lumateperone in bipolar depression, which represents greater unmet need and is a potentially larger market opportunity with fewer approved products,” Kulkarni stated. The analyst added, “Recall that in 1Q20, ITCI started another monotherapy Phase 3 trial (global) with results expected in 2H21. ITCI, however, expects to send in a supplemental new drug application (sNDA) for bipolar depression in late-2020. With a successful global monotherapy trial and a U.S. trial with mixed results, we believe ITCI has a solid shot at a potential approval in this indication.”The good news didn’t end there. Kulkarni believes that the possible upside drivers extend beyond lumateperone, with Phase 1/2 data for ITI-214 in heart failure expected in the next few weeks.It should come as no surprise, then, that Kulkarni stayed with the bulls. In addition to keeping a Buy rating on the stock, the analyst maintained a $70 price target, which brings the upside potential to 215%.Do other analysts agree with Kulkarni? As it turns out, they do. Only Buy ratings, 3 to be exact, have been received in the last three months, so the consensus rating is a Strong Buy. At $47.67, the average price target indicates 115% upside potential. (See Intra-Cellular stock-price forecast on TipRanks)To find good ideas for pharma stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Benzinga

    Benzinga's Top Upgrades, Downgrades For June 4, 2020

    Upgrades * For American Eagle Outfitters Inc (NYSE: AEO), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. For the first quarter, American Eagle Outfitters had an EPS of ($0.84), compared to year-ago quarter EPS of $0.24. The stock has a 52-week-high of $19.90 and a 52-week-low of $6.54. American Eagle Outfitters's stock last closed at $11.81 per share. * For Comerica Inc (NYSE: CMA), B. Riley FBR upgraded the stock from Neutral to Buy. In the first quarter, Comerica showed an EPS of ($0.46), compared to $2.08 from the year-ago quarter. The stock has a 52-week-high of $74.11 and a 52-week-low of $24.28. Comerica's stock last closed at $40.04 per share. * Oppenheimer upgraded the stock for Sally Beauty Holdings Inc (NYSE: SBH) from Perform to Outperform. Sally Beauty Holdings earned $0.23 in the second quarter, compared to $0.51 in the year-ago quarter. The stock has a 52-week-high of $21.98 and a 52-week-low of $6.28. Sally Beauty Holdings's stock last closed at $15.21 per share. * Citigroup changed the rating for SeaWorld Entertainment Inc (NYSE: SEAS) from Neutral to Buy. In the first quarter, SeaWorld Entertainment showed an EPS of ($0.72), compared to ($0.41) from the year-ago quarter. The stock has a 52-week-high of $36.96 and a 52-week-low of $6.75. SeaWorld Entertainment's stock last closed at $18.57 per share. * Baird changed the rating for Sykes Enterprises Inc (NASDAQ: SYKE) from Neutral to Outperform. Sykes Enterprises earned $0.44 in the first quarter, compared to $0.45 in the year-ago quarter. The stock has a 52-week-high of $38.24 and a 52-week-low of $22.12. Sykes Enterprises's stock last closed at $28.58 per share. * For Targa Resources Corp (NYSE: TRGP), Barclays upgraded the stock from Equal-Weight to Overweight. In the first quarter, Targa Resources showed an EPS of $0.00, compared to ($0.30) from the year-ago quarter. The stock has a 52-week-high of $43.47 and a 52-week-low of $3.66. Targa Resources's stock last closed at $20.47 per share. * Bernstein upgraded the stock for Tyson Foods Inc (NYSE: TSN) from Market Perform to Outperform. In the second quarter, Tyson Foods showed an EPS of $0.77, compared to $1.20 from the year-ago quarter. The stock has a 52-week-high of $94.24 and a 52-week-low of $42.57. Tyson Foods's stock last closed at $60.09 per share. * Deutsche Bank upgraded the stock for Wells Fargo & Co (NYSE: WFC) from Hold to Buy. Wells Fargo earned $0.80 in the first quarter, compared to $1.20 in the year-ago quarter. The stock has a 52-week-high of $54.75 and a 52-week-low of $22.00. Wells Fargo's stock last closed at $28.81 per share. * For Methanex Corp (NASDAQ: MEOH), ScotiaBank upgraded the stock from Sector Perform to Sector Outperform. In the first quarter, Methanex showed an EPS of $0.10, compared to $0.73 from the year-ago quarter. The stock has a 52-week-high of $47.55 and a 52-week-low of $9.00. Methanex's stock last closed at $19.42 per share. * For Evergy Inc (NYSE: EVRG), Evercore ISI Group upgraded the stock from In-Line to Outperform. Evergy earned $0.41 in the first quarter, compared to $0.44 in the year-ago quarter. The stock has a 52-week-high of $76.57 and a 52-week-low of $42.01. Evergy's stock last closed at $63.44 per share. Downgrades * Pareto changed the rating for International Seaways Inc (NYSE: INSW) from Buy to Hold. For the first quarter, International Seaways had an EPS of $1.49, compared to year-ago quarter EPS of $0.37. The stock has a 52-week-high of $31.39 and a 52-week-low of $14.89. International Seaways's stock last closed at $20.74 per share. * Citigroup changed the rating for Qudian Inc (NYSE: QD) from Neutral to Sell. Qudian earned ($0.50) in the first quarter, compared to $0.49 in the year-ago quarter. The stock has a 52-week-high of $9.21 and a 52-week-low of $1.21. Qudian's stock last closed at $1.54 per share. * Pareto changed the rating for Scorpio Tankers Inc (NYSE: STNG) from Buy to Hold. For the first quarter, Scorpio Tankers had an EPS of $0.82, compared to year-ago quarter EPS of $0.30. The stock has a 52-week-high of $40.45 and a 52-week-low of $12.35. Scorpio Tankers's stock last closed at $16.91 per share. * For Goldman Sachs Group Inc (NYSE: GS), Deutsche Bank downgraded the stock from Buy to Hold. Goldman Sachs Group earned $3.11 in the first quarter, compared to $5.71 in the year-ago quarter. The stock has a 52-week-high of $250.46 and a 52-week-low of $130.85. Goldman Sachs Group's stock last closed at $210.63 per share. * For Planet Fitness Inc (NYSE: PLNT), Raymond James downgraded the stock from Outperform to Market Perform. For the first quarter, Planet Fitness had an EPS of $0.16, compared to year-ago quarter EPS of $0.35. The stock has a 52-week-high of $88.77 and a 52-week-low of $23.77. Planet Fitness's stock last closed at $77.27 per share. Initiations * Guggenheim initiated coverage on BioXcel Therapeutics Inc (NASDAQ: BTAI) with a Buy rating. The price target for BioXcel Therapeutics is set at $101.00. BioXcel Therapeutics earned ($0.79) in the first quarter, compared to ($0.46) in the year-ago quarter. The stock has a 52-week-high of $51.83 and a 52-week-low of $3.76. BioXcel Therapeutics's stock last closed at $45.14 per share. * Roth Capital initiated coverage on Delcath Systems Inc (NASDAQ: DCTH) with a Buy rating. The price target for Delcath Systems is set at $20.00. In the first quarter, Delcath Systems showed an EPS of ($108.07), compared to ($0.11) from the year-ago quarter. The stock has a 52-week-high of $13.00 and a 52-week-low of $6.06. Delcath Systems's stock last closed at $7.75 per share. * With a rating of Neutral, Compass Point initiated coverage on Macerich Co (NYSE: MAC). The price target is set at $9.00 for Macerich. Macerich earned $0.81 in the first quarter, compared to $0.81 in the year-ago quarter. The stock has a 52-week-high of $37.82 and a 52-week-low of $4.81. Macerich's stock last closed at $8.58 per share. * With a rating of Overweight, Barclays initiated coverage on Plug Power Inc (NASDAQ: PLUG). The price target is set at $7.00 for Plug Power. In the first quarter, Plug Power showed an EPS of ($0.12), compared to ($0.15) from the year-ago quarter. The stock has a 52-week-high of $6.05 and a 52-week-low of $1.86. Plug Power's stock last closed at $4.17 per share. * With a rating of Outperform, RBC Capital initiated coverage on Provention Bio Inc (NASDAQ: PRVB). The price target is set at $25.00 for Provention Bio. For the first quarter, Provention Bio had an EPS of $0.26, compared to year-ago quarter EPS of ($0.29). The stock has a 52-week-high of $22.82 and a 52-week-low of $4.00. Provention Bio's stock last closed at $14.48 per share. * With a rating of Sell, Compass Point initiated coverage on Tanger Factory Outlet Centers Inc (NYSE: SKT). The price target is set at $6.00 for Tanger Factory Outlet. For the first quarter, Tanger Factory Outlet had an EPS of $0.50, compared to year-ago quarter EPS of $0.57. The stock has a 52-week-high of $17.94 and a 52-week-low of $4.05. Tanger Factory Outlet's stock last closed at $7.41 per share. * With a rating of Neutral, Compass Point initiated coverage on Taubman Centers Inc (NYSE: TCO). The price target is set at $42.00 for Taubman Centers. In the first quarter, Taubman Centers showed an EPS of $0.88, compared to $0.95 from the year-ago quarter. The stock has a 52-week-high of $53.40 and a 52-week-low of $26.24. Taubman Centers's stock last closed at $42.42 per share. * KeyBanc initiated coverage on PPD Inc (NASDAQ: PPD) with an Overweight rating. The price target for PPD is set at $35.00. In the first quarter, PPD earned $0.24. The stock has a 52-week-high of $33.23 and a 52-week-low of $10.61. PPD's stock last closed at $28.59 per share. * H.C. Wainwright initiated coverage on Actinium Pharmaceuticals Inc (AMEX: ATNM) with a Buy rating. The price target for Actinium Pharmaceuticals is set at $3.00. For the fourth quarter, Actinium Pharmaceuticals had an EPS of ($0.03), compared to year-ago quarter EPS of ($0.05). The stock has a 52-week-high of $0.41 and a 52-week-low of $0.16. Actinium Pharmaceuticals's stock last closed at $0.22 per share.See more from Benzinga * Duluth Holdings: Q1 Earnings Insights * Recap: Toro Q2 Earnings * Recap: Orion Energy Systems Q4 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • BTAI: Phase 3 Data from SERENITY Trials in July 2020…
    Zacks Small Cap Research

    BTAI: Phase 3 Data from SERENITY Trials in July 2020…

    By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT BioXcel Therapeutics, Inc. (NASDAQ:BTAI) currently has two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 – an immuno-oncology agent for treatment of a rare form of prostate cancer

  • BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript
    Motley Fool

    BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript

    Good morning, everyone, and thank you for joining our conference call to discuss BioXcel Therapeutics' financial results and business highlights for the first-quarter 2020. Joining me for the call today are Richard Steinhart, chief financial officer; Frank Yocca, chief scientific officer; and Vince O'Neill, chief medical officer.

  • How BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Can Impact Your Portfolio Volatility
    Simply Wall St.

    How BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Can Impact Your Portfolio Volatility

    If you're interested in BioXcel Therapeutics, Inc. (NASDAQ:BTAI), then you might want to consider its beta (a measure...

  • Benzinga

    The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...

  • Benzinga

    The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...

  • Get In on the AI Health Care Revolution With Globus, BioXcel, Apple, Amazon and Google
    GuruFocus.com

    Get In on the AI Health Care Revolution With Globus, BioXcel, Apple, Amazon and Google

    Market forecast to increase at more than 40% CAGR over next five years Continue reading...

  • We're Keeping An Eye On BioXcel Therapeutics's (NASDAQ:BTAI) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On BioXcel Therapeutics's (NASDAQ:BTAI) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. Indeed, BioXcel...

  • BTAI: Potentially Transformative Year Ahead for BioXcel…
    Zacks Small Cap Research

    BTAI: Potentially Transformative Year Ahead for BioXcel…

    By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update BXCL501 Update BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a clinical stage biopharmaceutical company focused on two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 –

  • Hedge Funds Have Never Been This Bullish On BioXcel Therapeutics, Inc. (BTAI)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On BioXcel Therapeutics, Inc. (BTAI)

    Is BioXcel Therapeutics, Inc. (NASDAQ:BTAI) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their […]

  • BTAI: Pivotal Phase 3 Trials for BXCL501 to Initiate by End of 2019…
    Zacks Small Cap Research

    BTAI: Pivotal Phase 3 Trials for BXCL501 to Initiate by End of 2019…

    By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Phase 3 Program for BXCL501 in Schizophrenia and Bipolar Disorder to Initiate Before End of 2019 On December 3, 2019, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced that following a successful ‘end-of-Phase 2’ meeting with the FDA, the company will be initiating the Phase 3 SERENITY (Sub-Lingual DExmedetomidine

  • BTAI: Phase 3 Trials of BXCL501 in Agitation to Initiate Before Year End…
    Zacks Small Cap Research

    BTAI: Phase 3 Trials of BXCL501 in Agitation to Initiate Before Year End…

    By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a biopharmaceutical company developing novel therapeutics using EvolverAI, the company’s proprietary research and development engine designed to utilize artificial intelligence (AI) and machine learning to evaluate millions of data points to identify new therapeutic

  • Zacks Small Cap Research

    BTAI: Initiating Coverage of BioXcel Therapeutics, Inc.; AI Driven Drug Development

    By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI INITIATION REPORT HERE Initiating Coverage We are initiating coverage of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) with a valuation of $21.00. BioXcel Therapeutics is a biopharmaceutical company utilizing an artificial-intelligence (AI) based approach to drug development. In combination with large datasets, the company uses a proprietary machine

  • How Many BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • Is BioXcel Therapeutics (NASDAQ:BTAI) A Risky Investment?
    Simply Wall St.

    Is BioXcel Therapeutics (NASDAQ:BTAI) A Risky Investment?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Benzinga

    BioXcel's CEO On BXCL501: 'This Is A Pretty Unique Drug'

    BioXcel Therapeutics (NASDAQ: BTAI) is a biotech company that is using artificial intelligence to identify neuroscience and immuno-oncology medicines. The company announced positive results Monday from its BXCL501 Phase 1b trial. Benzinga connected with BioXcel's CEO Dr. Vimal Mehta for more insight on the company's results and plans moving forward.